ROSEMONT, Pa. — Medunik USA, a company dedicated to improving the health and quality of life of Americans with rare diseases by making orphan drugs available in the U.S., announced that Siklos (hydroxyurea), an FDA-approved orphan drug, is now available in 100 mg tablets for pharmacies to order.

Siklos is indicated to reduce the frequency of painful crises and the need for blood transfusions in pediatric patients, two years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises. It is the first and only FDA-approved hydroxyurea-based treatment for use in pediatric patients with sickle cell anemia.

Medunik USA holds the exclusive rights to market and distribute Siklos in the United States, through an agreement with AddMedica, a French pharmaceutical company specializing in hematology.

“We are pleased to partner with AddMedica to provide access to an orphan drug therapy that can contribute to reducing painful crises, specifically for children with sickle cell anemia,” said Éric Gervais, executive vice president of Medunik. “The addition of Siklos to the Medunik portfolio establishes our footprint in the United States in the area of orphan drug therapies and is the latest in a series of significant advances for our company.”

“Medunik USA is well positioned to ensure both the marketing and distribution of Siklos in the United States, thanks to their knowledge of the orphan drug commercialization process. We are pleased to count them as a partner,” said Bernard Dauvergne, executive director of AddMedica.